Neoprobe to Present at Credit Suisse 2nd Annual Small & Mid Cap Conference
September 22 2011 - 8:40AM
Business Wire
Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer
of innovative oncology surgical and diagnostic products, today
announced that Dr. Mark Pykett, Neoprobe’s President and Chief
Executive Officer, will deliver a presentation to institutional
investors at 1:50 PM ET, Wednesday, September 28, 2011 at the
Credit Suisse 2nd Annual Small & Mid Cap Conference, taking
place at Le Parker Meridien Hotel, New York.
During the conference, Dr. Pykett will be available to meet with
institutional investors to discuss recent developments and the
Company’s growth strategy. Presentations at the conference are not
being webcast; however slides from Dr. Pykett’s presentation will
be available at the Company’s website at www.neoprobe.com.
About Neoprobe
Neoprobe Corporation (NYSE Amex: NEOP) is a biomedical company
focused on enhancing oncology patient care and improving patient
benefit through radiopharmaceutical product development. Neoprobe
is actively developing two radiopharmaceutical agent platforms –
Lymphoseek® and RIGScanTM CR – to help surgeons better identify and
treat certain types of cancer. Neoprobe’s subsidiary, Cira
Biosciences, Inc., is also exploring development of a
patient-specific cellular therapy technology platform called ACT.
Neoprobe’s strategy is to deliver superior growth and shareholder
return by bringing to market novel radiopharmaceutical agents and
advancing the Company’s pipeline program through continued
investment and selective acquisitions. For more information, please
visit www.neoprobe.com.
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
From May 2024 to Jun 2024
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
From Jun 2023 to Jun 2024
